Finance

Lists
Q1 2027 earnings • released • Revenue beat +13.49%
See results
4506:TYO
Sumitomo Pharma Co Ltd
¥1,270.50
+1.80%
(+22.50) 1D
Aug 3, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4506...
Open
¥1,218
High
¥1,294
Low
¥1,204
Mkt. cap
570.71B
Avg. vol.
3.38M
Volume
6.68M
P/E ratio
4.54
52-wk high
¥3,288
52-wk low
¥1,190
EPS
¥280
Shares outstanding
397.30M
No. of employees
3K
Open
¥1,218
High
¥1,294
Low
¥1,204
Mkt. cap
570.71B
Avg. vol.
3.38M
Volume
6.68M
P/E ratio
4.54
52-wk high
¥3,288
52-wk low
¥1,190
EPS
¥280
Shares outstanding
397.30M
No. of employees
3K
News stories
From sources across the web
Profile
Sumitomo Pharma Company Limited is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka. Wikipedia
About Sumitomo Pharma Co Ltd
CEO-
Employees3.12K
FoundedMay 14, 1897
HeadquartersOsaka, Osaka, Japan
SectorPharmaceutical industry
Websitesumitomo-pharma.co.jp
Last report
Jul 31, 2026
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
129.50B / 114.10B
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
119.12B
120.62B
105.55B
129.50B
Cost of goods sold
45.59B
55.44B
51.26B
61.41B
Cost of revenue
45.59B
55.44B
51.26B
61.41B
Research and development expenses
9.35B
10.35B
16.12B
11.43B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
40.90B
42.94B
43.52B
39.24B
Operating expense
-1.04B
52.19B
110.09B
50.33B
Total operating expenses
44.55B
107.63B
161.36B
111.74B
Operating income
74.57B
13.00B
-55.81B
-
Other non operating income
-
-
-1.64B
-
EBT including unusual items
80.87B
8.74B
-1.20B
18.30B
EBT excluding unusual items
80.87B
8.74B
-51.00B
18.30B
Income tax expense
-6.78B
-80.00M
-383.00M
1.30B
Effective tax rate
-8.39%
-0.92%
32.05%
7.09%
Other operating expenses
-51.30B
-1.10B
50.45B
-337.00M
Net income
87.65B
8.82B
-812.00M
17.00B
Net profit margin
73.58%
7.31%
-0.77%
13.13%
Earnings per share
-
-
-
-
Interest and investment income
5.11B
258.00M
4.64B
2.20B
Interest expense
-
-5.14B
-
-2.09B
Net interest expenses
5.11B
-4.88B
4.64B
107.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
79.85B
18.32B
-52.48B
22.65B
Gain or loss from assets sale
1.96B
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps